Favorable outcome | Unfavorable outcome | ||
---|---|---|---|
(n = 76) | (n = 47) | p-value | |
Female | 42 (55%) | 27 (57%) | 0.81 |
Age, yr | 61.1 ± 16.1 | 60.4 ± 15.4 | 0.81 |
Observational period, yr | 7.2 ± 4.6 | 8.7 ± 7.7 | 0.22 |
Subtype | |||
Early-onset | 23 (30%) | 18 (38%) | 0.33 |
Late-onset | 42 (55%) | 26 (55%) | 1.00 |
Thymoma-associated | 11 (14%) | 3 (6%) | 0.17 |
Symptoms | |||
Ptosis and diplopia | 49 (64%) | 32 (68%) | 0.68 |
Ptosis alone | 22 (29%) | 14 (30%) | 0.92 |
Diplopia alone | 5 (7%) | 1 (2%) | 0.26 |
Anti-acetylcholine receptor positive | 60 (79%) | 32 (68%) | 0.18 |
Treatment | |||
Acetyl-cholinesterase inhibitors | 58 (86%) | 41 (78%) | 0.14 |
Pyridostigmine (mg/day) | 79.7 ± 66.6 | 132.0 ± 54.0 | <0.0001 |
Oral prednisolone | 27 (36%) | 25 (53%) | 0.053 |
Maximum dose (mg/day) | 19.4 ± 10.4 | 21.5 ± 15.5 | 0.58 |
Immunosuppressants | 14 (18%) | 14 (30%) | 0.14 |
mPSL | 11 (14%) | 12 (26%) | 0.13 |
Plasmapheresis | 2 (3%) | 4 (9%) | 0.14 |
Immunoglobulin | 1 (1%) | 0 (0%) | 0.43 |
Thymectomy | 20 (26%) | 11 (23%) | 0.71 |
Ocular-QMG score | |||
Pre-treatment | 3.4 ± 1.7 | 4.5 ± 1.7 | 0.006 |
Post-treatment | 0.6 ± 0.8 | 3.4 ± 2.1 | <0.0001 |
MG-QOL15-J score | 5.7 ± 8.5 | 15.7 ± 12.7 | <0.0001 |